Oxford, UK – 29 May 2019: Oxford Biomedica plc (LSE:Oxford Biomedica), a leading gene and cell therapy group, today announces that, further to the announcement of 28 May in relation to Novo Holdings’ agreement to subscribe for 6,568,024 new ordinary shares in Oxford Biomedica (the “Subscription Shares”) at a price of £6.90 per share (the “Subscription Price”), Novo Holdings has now exercised in full its option under the Subscription Agreement to subscribe to a further 1,181,976 new ordinary shares (the “Further Shares”) in Oxford Biomedica at the Subscription Price (the “Subscription Option”). Exercise of the Subscription Option will increase Novo Holdings’ ownership to 10.1% of Oxford Biomedica.
Application has been made for the Further Shares to be admitted to the premium listing segment of the Official List of the Financial Conduct Authority and to be admitted to trading on the main market for listed securities of the London Stock Exchange plc (together, “Admission”). Admission of the Further Shares is expected to take place at 8.00 a.m. on 4 June 2019.
-Ends-
Enquiries:
Oxford Biomedica plc
John Dawson, Chief Executive Office | T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer | T: +44 (0)1865 783 000
Catherine Isted, Head of Corporate Development & IR | T: +44 (0)1865 954 161 / E: ir@oxb.com
Sarah MacLeod, Head of Communications | T: +44 (0)7747 602 739 / E: media@oxb.com
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal | T: +44 (0)20 3709 5700
About Oxford Biomedica
Oxford Biomedica (LSE:Oxford Biomedica) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the “Group”) have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people. Further information is available at www.oxb.com